Biologics is an increasingly important area of research for drug discovery, due to the lack of off-target toxicity, which essentially eliminates one of the principal causes of failures in small-molecule drug development. Biologics
now account for the fastest-growing segment of prescription drug spending.
The public domain repository of 3D experimental protein structure data includes a large number of antibody structures, as do inhouse repositories within drug discovery research organisations, and the number of these structures is growing rapidly. In response to this increasingly important area of modern drug discovery, we have developed an enterprise protein structure database system designed for Structure Based Drug Discovery (SBDD) that effectively and efficiently handles assemblies involving antibodies.
Proasis Ab is a full scale enterprise ‘pop-up’ version of Proasis. It contains all the functionality of Proasis4 including our industry leading proprietary methods. It can:
For more information, or to organise a demonstration of ProasisAb, please contact us.